Sign up to save your podcasts
Or
Share Tanya Siddiqi, MD - Addressing Patient Needs With CAR T-Cell Therapy in the Treatment of CLL/SLL: Preparing for an Evolving Treatment Paradigm
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Tanya Siddiqi, MD - Addressing Patient Needs With CAR T-Cell Therapy in the Treatment of CLL/SLL: Preparing for an Evolving Treatment Paradigm
Please visit answersincme.com/DTC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and the future use of CAR T-cell therapies. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs in the management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); Describe the clinical evidence of novel and emerging therapies being investigated to address unmet therapeutic needs in the management of CLL/SLL; and Outline considerations for optimizing the future use of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with relapsed/refractory CLL/SLL.
View all episodes
By Answers in CME
5
66 ratings
Please visit answersincme.com/DTC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and the future use of CAR T-cell therapies. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs in the management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); Describe the clinical evidence of novel and emerging therapies being investigated to address unmet therapeutic needs in the management of CLL/SLL; and Outline considerations for optimizing the future use of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with relapsed/refractory CLL/SLL.
More shows like CME in Minutes: Education in Oncology & Hematology
View all
Planet Money
30,683 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
12 Listeners
This Week in Cardiology
881 Listeners
Oncology Today with Dr Neil Love
57 Listeners
CCO Oncology Podcast
9 Listeners
CME in Minutes: Education in Dermatology
3 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
43 Listeners
CME in Minutes: Education in Ophthalmology
0 Listeners
CME in Minutes: Education in Cardiology & Pulmonology
3 Listeners
CME in Minutes: Education in Primary Care
6 Listeners
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
5 Listeners